GlassScriptPhysician profile
John M Brennan
NPI 1336123173
$19,223.46
in general payments reported to CMS, 2019-2025
37 companies · $3,051 in 2025
The $3,051 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,897 · 2020: $1,929 · 2021: $4,206 · 2022: $2,366 · 2023: $2,257 · 2024: $2,518 · 2025: $3,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,812 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,811.89 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $2,382.72 | 2019-2025 | Aplenzin, Wellbutrin |
| Validus Pharmaceuticals LLC | $1,711.96 | 2019-2025 | Equetro, Equetro, Raldesy |
| Otsuka America Pharmaceutical, INC. | $1,586.42 | 2019-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,305.37 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,210.19 | 2019-2025 | Rexulti, Brintellix, Abilify Asimtufii |
| Almatica Pharma LLC | $1,052.11 | 2021-2025 | Loreev Xr |
| Abbvie INC. | $1,020.41 | 2021-2025 | Vraylar |
| Tris Pharma INC | $975.64 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Takeda Pharmaceuticals U.S.A., INC. | $951.45 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $921.92 | 2019-2025 | Adzenys Xr-Odt |
| Alkermes, INC. | $840.10 | 2021-2025 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $692.66 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $551.87 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $475.69 | 2021-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $454.94 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.